GlassScriptPhysician profile
Jilu J Varghese
NPI 1386875698
$3,945.36
in general payments reported to CMS, 2019-2025
24 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $31.74 · 2021: $225 · 2022: $776 · 2023: $910 · 2024: $788 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $701.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $670.04 | 2022-2025 | |
| Abbvie INC. | $484.70 | 2022-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $431.77 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $285.47 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $223.80 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $165.75 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $160.04 | 2023-2024 | Inspire |
| Lilly USA, LLC | $157.11 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $142.30 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $132.78 | 2025 | Zoryve |
| Exact Sciences Corporation | $63.87 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $57.17 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $54.06 | 2023-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2019-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.11 | 2021 | |
| Boston Scientific Corporation | $29.73 | 2024 | Wavewriter Alpha Prime 16 |
| Optinose US, INC. | $24.96 | 2025 | |
| Sanofi Pasteur INC. | $20.82 | 2019 | |
| Edwards Lifesciences Corporation | $17.62 | 2024 | Sapien 3 Ultra Resilia |
| Currax Pharmaceuticals LLC | $16.83 | 2024 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $13.43 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jilu Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.